(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 November 2022 (17.11.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/238347 A1

(51) International Patent Classification:
C07D 401/12 (2006.01) *C07D 471/08* (2006.01)
C07D 403/12 (2006.01) *A61P 11/06* (2006.01)
C07D 405/14 (2006.01) *A61K 31/53* (2006.01)

(21) International Application Number:
PCT/EP2022/062525

(22) International Filing Date:
10 May 2022 (10.05.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

21173452.0	12 May 2021 (12.05.2021)	EP
21209447.8	22 November 2021 (22.11.2021)	EP
21215859.6	20 December 2021 (20.12.2021)	EP

(71) Applicant *(for all designated States except IQ, US)*: **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(71) Applicant *(for US only)*: **HOFFMANN-LA ROCHE INC.** [US/US]; Overlook at Great Notch, 150 Clove Road, 8th Floor, Suite 8 - Legal Department, Little Falls, New Jersey 07424 (US).

(72) Inventors: **BOUCHE, Lea Aurelie**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). **GUBA, Wolfgang**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). **JAESCHKE, Georg**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). **MESCH, Stefanie Katharina**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). **TOSSTORFF, Andreas Michael**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH).

(74) Agent: **JOCHNOWITZ, Evan**; c/o F. Hoffmann-La Roche AG, Patent Department, Grenzacherstrasse 124, 4070 Basel (CH).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*

(54) Title: NLRP3 INHIBITORS



Ib

(57) Abstract: The invention relates to novel compounds having the general formula Ib Ib wherein R^1, R^2, R^3, R^4, R^5, and Z are as described herein, composition including the compounds and methods of using the compounds.

WO 2022/238347 A1